Taken together, NY-ESO-1 specific TCR-T cells targeting DAC-treated GBM cells polyfunctionally secrete effector and immune-signaling factors that contribute to effective clearance of NY-ESO-1–expressing tumor cells. The gene discussed is CTAG1A; the disease is glioblastoma.